Stem cell results vary because patients can respond differently even to the same treatment. Reports may also involve different diseases, cell products, doses, delivery methods, and definitions of success. An outcome from a blood stem cell transplant cannot predict the outcome of an unrelated clinic injection. One person’s improvement does not reliably predict yours.Stem cell transplantImportant patient and consumer information about regenerative medicine therapies
There are two questions to separate: why people respond differently to a treatment that has evidence behind it, and whether an unproven treatment caused the improvement being reported. Mixed testimonials alone cannot answer the second question.Important patient and consumer information about regenerative medicine therapies

Different diseases and treatment goals
“Stem cell therapy” is not a single treatment. Blood-forming stem cell transplants restore blood cell production after high-dose treatment for certain cancers and other disorders. Their suitability depends on the diagnosis, disease stage, previous treatment, and general health. That evidence cannot simply be transferred to a cell injection offered for joint pain or another unrelated condition.Stem cell transplantImportant patient and consumer information about regenerative medicine therapies
Approval is specific to a product, patient group, and use. For example, on December 18, 2024, the U.S. FDA approved Ryoncil (remestemcel-L-rknd), its first mesenchymal stromal cell (MSC) therapy. This donor bone-marrow-derived product was approved for steroid-refractory acute graft-versus-host disease in children aged 2 months and older. That decision is not evidence that MSC injections work for unrelated conditions.Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host
The same label can hide different products
Blood-forming stem cells and mesenchymal stromal cells are different cell types. Bone marrow, blood, cord blood, and fat-derived preparations should not be treated as interchangeable products. Source, processing, storage, and testing matter when identifying what was actually given.Stem cell transplantImportant patient and consumer information about regenerative medicine therapies
For blood stem cell transplants, the NCI distinguishes autologous cells from the patient and allogeneic cells from a donor; cells from an identical twin are called syngeneic. Your own cells match you, although there can be a risk of returning cancer cells with the transplant. With donor cells, matching helps reduce rejection and graft-versus-host disease. Rejection means the recipient’s immune system attacks the graft; graft-versus-host disease occurs when donor immune cells attack the recipient’s tissues.Stem cell transplant
A listing under regenerative medicine does not establish effectiveness. Nor is the FDA’s combined cellular and gene therapy list a count of interchangeable stem cell treatments: each listed product has its own approved use.Approved cellular and gene therapy products
When comparing reports, check the actual dose, the proportion of viable cells, the delivery route, and the treatment schedule. A higher cell count or more sessions is not, by itself, evidence of greater benefit. A vein infusion and a local injection are not the same procedure; evidence needs to match the product and how it was used.Important patient and consumer information about regenerative medicine therapies
Patients differ even under one protocol
Receiving the same protocol does not make two patients medically identical. In the transplant setting, the NCI identifies the transplant type, previous treatment doses, response to that treatment, cancer type and stage, and health before transplant as factors affecting how a patient feels afterward. These differences help explain why another patient’s recovery is not a timetable for yours.Stem cell transplant
The infusion itself can take 1 to 5 hours, but immune recovery takes much longer: several months after an autologous transplant and 1 to 2 years after an allogeneic or syngeneic transplant. These are transplant recovery estimates, not waiting periods for an unrelated injection to “start working.”Stem cell transplant
Benefits also need to be weighed against harms. Transplant-related risks include infection, bleeding, infertility, and organ injury; donor transplants can cause graft-versus-host disease. Separately, the FDA has received reports of serious harm from unapproved regenerative products, including infections, blindness, and tumor formation. The risks of one procedure should not be used as a substitute for the safety evidence on another.Stem cell transplantImportant patient and consumer information about regenerative medicine therapies
Success depends on what was measured
A report of less pain, a longer walking distance, an imaging change, and a blood test result describes different outcomes. Feeling better does not, on its own, demonstrate tissue regeneration. To interpret a result, you need the starting measurement, the amount of change, and the follow-up period.
A comparison group helps researchers ask whether improvement exceeds what happens with another treatment or standard care. Random assignment helps reduce bias from differences between the groups. The NCI explains these principles in its guidance on clinical trials; they are reasons to look beyond a before-and-after story, not proof that any particular stem cell intervention works.How trials work
A practical comparison scenario
Consider a hypothetical comparison, not a patient case: one report records pain four weeks after treatment, while another measures walking ability six months later. The reports do not establish that one treatment worked better. First check whether the diagnosis, product, starting condition, outcome measure, and follow-up match. Also check whether medication or rehabilitation differed.
| Possible difference | What to request | What it helps you avoid |
|---|---|---|
| Disease and starting condition | Diagnosis, stage or severity, prior treatment, and baseline score | Comparing people with substantially different health problems |
| Product and delivery | Cell type, source, processing, dose, viability, route, and schedule | Treating a shared “stem cell” label as the same intervention |
| Definition of success | The outcome specified before treatment and the actual change measured | Equating symptom relief with proof of tissue repair |
| Follow-up and other care | Assessment dates, rehabilitation, medication changes, and additional procedures | Comparing different time points or ignoring other explanations |
| Evidence and harms | Study design, number treated, comparison group, missing follow-up, and adverse events | Judging benefit from selected positive reports alone |
Why testimonials do not settle the question
A testimonial describes an individual report, not a controlled comparison. It may leave out other care, people who did not improve, adverse events, or people who never returned for follow-up. Without those details, you cannot tell how representative the story is or whether the intervention caused the change.How trials work
Study registration is not proof of effectiveness. The FDA specifically warns that a ClinicalTrials.gov listing or a firm’s FDA registration does not establish that a regenerative product is legally marketed.Important patient and consumer information about regenerative medicine therapies Finding a paper in a database is a starting point for appraisal, not a substitute for examining its methods and relevance.How trials work
Regulatory status is a separate check
An established transplant procedure, an approved cell product, an investigational intervention, and a private clinic service are not equivalent categories. Being available for purchase does not demonstrate benefit, and U.S. FDA status does not determine the legal status of a service in Japan.Stem cell transplantImportant patient and consumer information about regenerative medicine therapies
In Japan, regenerative medicine provision plans fall under a framework with risk-based procedures, committee oversight, and reporting requirements. MHLW’s guidance distinguishes research from non-research provision. Filing a plan should not be read as proof that the intervention works for your disease.Plan
If you travel for care, request the exact product or procedure, proposed indication, relevant plan or approval details, and supporting human evidence in writing. A general claim that a clinic is “registered” does not answer those questions.
What this means for your decision
There is no single meaningful success rate for “stem cell therapy” as a whole. The useful evidence concerns a defined treatment for a defined condition in comparable patients, with a stated outcome and follow-up. For an unproven intervention, conflicting stories may reflect uncertainty about effectiveness rather than a known treatment that simply works for some people.Stem cell transplantImportant patient and consumer information about regenerative medicine therapies
Before deciding, take the proposed protocol and the comparison questions above to your treating clinician. Ask what benefit is realistic, what counts as no benefit, which alternatives have stronger evidence, what harms require urgent care, and who provides follow-up if you return home. Be cautious about guaranteed results or claims that one person’s improvement predicts yours.Important patient and consumer information about regenerative medicine therapies
Questions about an appointment at GINZA NOA CLINIC?
Contact the independently operated patient support team for appointment enquiries, not medical advice. Begin with a general question; do not send your full medical history in an initial message. A clinician must assess treatment suitability.
This article explains evidence and comparison methods; it does not report the author’s clinical experience or provide individual medical advice. Your care team should interpret any proposed treatment in light of your diagnosis, current care, and risks.




